Biotech Values

[DewDiligence]

That may be the case...I have no idea. But that language is the sort of slippery slope to false claims and excuses that we would criticize other companies for deploying.

I don’t get your point about a “slippery slope.”

DEB025 is fundamentally different from HCV protease inhibitors and polymerase inhibitors insofar as it targets a host protein rather than a viral protein. Whether this has anything to do with the way NVS is reporting the DEB025 clinical data is unclear to me, but I think it’s reasonable to presume that there will be some differences in the safety and efficacy metrics employed, if there have not been already.

NVS certainly doesn’t want or need to concoct new clinical metrics just to impress the investment community, if that’s what you’re suggesting.